CJC-1295 DAC Research Peptide — Scientific Overview
CJC-1295 with DAC (Drug Affinity Complex) is a specific formulation of the CJC-1295 GHRH analog that includes a reactive maleimide-linker (the DAC component) capable of covalently binding to the free cysteine residue (Cys-34) on human serum albumin. This covalent albumin binding is what gives CJC-1295 DAC its dramatically extended plasma half-life — approximately 6-8 days in animal models compared to only 6-7 minutes for native GHRH — making it suitable for research protocols requiring prolonged, sustained GHRH receptor activation.
CJC-1295 DAC shares the same backbone as CJC-1295 No DAC (Mod GRF 1-29) — the first 29 amino acids of GHRH with four amino acid substitutions to improve DPP-IV resistance — but adds the albumin-binding linker for pharmacokinetic extension. The two forms serve different research purposes: DAC form for sustained, tonic GH stimulation studies; No DAC form for pulsatile, physiological-mimicking stimulation studies.
Research Background
Published research using CJC-1295 DAC includes Phase I/II clinical pharmacokinetic studies by ConjuChem Biotechnologies that characterized its GH and IGF-1 stimulation profiles in human subjects with GH deficiency. Preclinical research has examined its body composition effects, metabolic parameters, and long-term GH axis stimulation in animal models. The clinical safety and pharmacokinetic data from ConjuChem trials provides important context for understanding CJC-1295 DAC behavior in research settings.
Key Research Areas
- GH Axis Research: Sustained GHRH receptor stimulation and prolonged GH secretion studies
- Pharmacokinetic Research: Albumin-binding technology and extended half-life peptide design
- IGF-1 Research: GH-mediated IGF-1 production and signaling pathway studies
- Body Composition Research: GH axis effects on fat and lean mass parameters in animal models
- Pituitary Research: Somatotroph cell function studies under sustained GHRH stimulation
- GHRH Biology: GHRH receptor pharmacology and downstream signaling research
Technical Specifications
| Parameter |
Value |
| Classification |
GHRH Analog with DAC (albumin-binding) |
| Molecular Weight |
~3647 Da (peptide) + ~500 Da (DAC linker) |
| Purity |
≥98% (HPLC-verified) |
| Form |
Lyophilized powder, sealed under argon |
| Storage |
−20°C (long-term) |
| Documentation |
Batch-specific COA (HPLC + Mass Spec) |
Storage & Handling (Research Laboratories)
Lyophilized CJC-1295 DAC should be stored at −20°C for long-term preservation, protected from light and moisture. For short-term active research use, 4°C storage is acceptable for up to approximately 4 weeks. Minimize repeated freeze-thaw cycles. Follow standard laboratory peptide reconstitution and handling protocols for all experimental use.
Frequently Asked Questions — CJC-1295 DAC Research
What does DAC stand for and how does it extend CJC-1295’s half-life?
DAC stands for Drug Affinity Complex — a technology developed by ConjuChem Biotechnologies that uses a reactive maleimide group to covalently attach a peptide to the free cysteine (Cys-34) on circulating human serum albumin. Albumin is the most abundant plasma protein with a half-life of approximately 19 days in humans. By binding covalently to albumin, CJC-1295 DAC effectively adopts albumin’s long circulating half-life, extending its own plasma half-life from the 6-7 minutes of native GHRH to approximately 6-8 days in animal models and similar extended pharmacokinetics in human clinical studies.
When should CJC-1295 DAC be used instead of CJC-1295 No DAC in research?
The choice between CJC-1295 DAC and No DAC depends on the experimental protocol. DAC form is appropriate for research requiring sustained, tonic GH elevation (approximating a continuous GHRH infusion) over several days. No DAC (Mod GRF 1-29) is appropriate for research mimicking more physiological pulsatile GH secretion — the peptide acts and clears rapidly, similar to natural pulsatile GHRH release. Studies examining long-term metabolic or body composition effects often use the DAC form; studies examining GH pulse dynamics typically use the No DAC form.
What clinical research has been conducted with CJC-1295 DAC?
ConjuChem conducted Phase I and Phase II clinical trials with CJC-1295 DAC in GH-deficient adults and healthy volunteers. The key publication (Jetté et al., 2005, Journal of Clinical Endocrinology & Metabolism) documented dose-dependent GH stimulation lasting for weeks after a single injection, and sustained elevation of plasma IGF-1 levels with acceptable tolerability profiles. These clinical pharmacokinetic studies established the albumin-binding mechanism’s effectiveness in humans and informed ongoing research.
Is CJC-1295 DAC approved for human use?
No. CJC-1295 DAC did not receive FDA or regulatory approval for human clinical use. Research Peptides Supplies supplies it for qualified laboratory research use only in controlled research settings by trained professionals.
What documentation accompanies CJC-1295 DAC?
CJC-1295 DAC from Research Peptides Supplies is verified at ≥98% purity by HPLC, with identity confirmed by Mass Spectrometry. A batch-specific COA documenting lot, HPLC result, mass data, and methodology is provided with every order.
⚗️ Research Use Only: This product is strictly intended for qualified laboratory and scientific research use by trained professionals in appropriate laboratory settings. It is not intended for human or veterinary administration, therapeutic use, food supplement applications, or any use outside controlled research environments. Not for human consumption.
